Aerogen Nebuliser Versus Standard Nebulised Therapy in Acute Chronic Obstructive Pulmonary Disease
COPD
About this trial
This is an interventional treatment trial for COPD
Eligibility Criteria
Inclusion Criteria:
- - Documented diagnosis of COPD
- Smoking history of at least 10 pack years (i.e. 20 cigarettes a day for 10 years or equivalent) or other risk factor for COPD in history (e.g. occupational exposure or alpha 1 antitrypsin deficiency)
- Age > 40 years old
Exclusion Criteria:
- - A lack of valid consent from patient (e.g. reduced level of consciousness, dementia)
- Patient unable to speak adequate English - as this study is being conducted in the Emergency Department, there is no access to translators
- Patient refusal
- Ambiguity over diagnosis of COPD e.g. possible underlying asthma
- Patients where an alternate diagnosis (such as congestive cardiac failure) cannot be excluded as the acute medical problem leading to shortness of breath
Sites / Locations
- Chelsea and Westminster Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Control nebuliser treatment
Treatment nebuliser treatment
Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care. Interventions: Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage) Arterial blood gas changes - pH, pO2, pCO2
Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen. Interventions: Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage) Arterial blood gas changes - pH, pO2, pCO2